A new pain reliever called Mobic showed an “increased risk” for heart attacks in preliminary data, a veteran U.S. Food and Drug Administration scientist told a panel of FDA advisors on Thursday.The drug, made by privately-held Boehringer Ingelheim Pharmaceuticals, showed the higher risk in one study, said David Graham, associate director for science and medicine at the FDA’s Office of Drug Safety. He added it was the only study on the issue.
